BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 34070951)

  • 1. Diagnostic and Prognostic Value of Circulating Cell-Free DNA for Cholangiocarcinoma.
    Wintachai P; Lim JQ; Techasen A; Lert-Itthiporn W; Kongpetch S; Loilome W; Chindaprasirt J; Titapun A; Namwat N; Khuntikeo N; Jusakul A
    Diagnostics (Basel); 2021 May; 11(6):. PubMed ID: 34070951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bile-derived circulating extracellular miR-30d-5p and miR-92a-3p as potential biomarkers for cholangiocarcinoma.
    Han HS; Kim MJ; Han JH; Yun J; Kim HK; Yang Y; Kim KB; Park SM
    Hepatobiliary Pancreat Dis Int; 2020 Feb; 19(1):41-50. PubMed ID: 31784323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum cell-free DNA methylation of OPCML and HOXD9 as a biomarker that may aid in differential diagnosis between cholangiocarcinoma and other biliary diseases.
    Wasenang W; Chaiyarit P; Proungvitaya S; Limpaiboon T
    Clin Epigenetics; 2019 Mar; 11(1):39. PubMed ID: 30832707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the Sequences of Circulating Tumor DNA of Cholangiocarcinomas and Its Applications and Limitations in Clinical Practice.
    Kim KH; Yi HS; Lee H; Bae GE; Yeo MK
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of bile acid profile in plasma to differentiate cholangiocarcinoma from benign biliary diseases and healthy controls.
    Zhang X; Yang Z; Shi Z; Zhu Z; Li C; Du Z; Zhang Y; Wang Z; Jiao Z; Tian X; Zhang J; Zhai W; Kan Q
    J Steroid Biochem Mol Biol; 2021 Jan; 205():105775. PubMed ID: 33130021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of Plasma Cell-Free DNA and MiRNA in Cholangiocarcinoma and Opisthorchiasis Viverrini Patients.
    Prasopdee S; Pholhelm M; Yusuk S; Tangphatsornruang S; Butthongkomvong K; Kunjantarachot A; Phanaksri T; Kulsantiwong J; Tesana S; Thitapakorn V
    Asian Pac J Cancer Prev; 2024 Mar; 25(3):739-746. PubMed ID: 38546056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating tumor DNA tracking through driver mutations as a liquid biopsy-based biomarker for uveal melanoma.
    Bustamante P; Tsering T; Coblentz J; Mastromonaco C; Abdouh M; Fonseca C; Proença RP; Blanchard N; Dugé CL; Andujar RAS; Youhnovska E; Burnier MN; Callejo SA; Burnier JV
    J Exp Clin Cancer Res; 2021 Jun; 40(1):196. PubMed ID: 34134723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High expression of protein tyrosine phosphatase receptor S (PTPRS) is an independent prognostic marker for cholangiocarcinoma.
    Lertpanprom M; Silsirivanit A; Tippayawat P; Proungvitaya T; Roytrakul S; Proungvitaya S
    Front Public Health; 2022; 10():835914. PubMed ID: 35991009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perioperative Circulating Tumor DNA in Colorectal Liver Metastases: Concordance with Metastatic Tissue and Predictive Value for Tumor Burden and Prognosis.
    He Y; Ma X; Chen K; Liu F; Cai S; Han-Zhang H; Hou T; Xiang J; Peng J
    Cancer Manag Res; 2020; 12():1621-1630. PubMed ID: 32184665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Resolvin D1 in the Differential Diagnosis of the Cholangiocarcinoma and Benign Biliary Diseases.
    Gül-Utku Ö; Karatay E; Ergül B; Kisa Ü; Erdin Z; Oğuz D
    Clin Lab; 2020 May; 66(5):. PubMed ID: 32390401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value of early kinetics of ctDNA combined with cfDNA and serum CEA for EGFR-TKI treatment in advanced non-small cell lung cancer.
    Zheng J; Wang Y; Hu C; Zhu M; Ii J; Lin C; Lu C; Dou Y; Zhao C; Zhang Y; Wu D; Li L; Tang H; He T; Pan C; Han R; He Y
    Thorac Cancer; 2022 Nov; 13(22):3162-3173. PubMed ID: 36193794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma.
    Lapitz A; Azkargorta M; Milkiewicz P; Olaizola P; Zhuravleva E; Grimsrud MM; Schramm C; Arbelaiz A; O'Rourke CJ; La Casta A; Milkiewicz M; Pastor T; Vesterhus M; Jimenez-Agüero R; Dill MT; Lamarca A; Valle JW; Macias RIR; Izquierdo-Sanchez L; Pérez Castaño Y; Caballero-Camino FJ; Riaño I; Krawczyk M; Ibarra C; Bustamante J; Nova-Camacho LM; Falcon-Perez JM; Elortza F; Perugorria MJ; Andersen JB; Bujanda L; Karlsen TH; Folseraas T; Rodrigues PM; Banales JM
    J Hepatol; 2023 Jul; 79(1):93-108. PubMed ID: 36868481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic value of serum bile acid composition patterns and serum glycocholic acid levels in cholangiocarcinoma.
    Proungvitaya S; Sombattheera S; Boonsiri P; Limpaiboon T; Wongkham S; Wongkham C; Titapun A; Proungvitaya T
    Oncol Lett; 2017 Oct; 14(4):4943-4948. PubMed ID: 29085505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell-free DNA from bile outperformed plasma as a potential alternative to tissue biopsy in biliary tract cancer.
    Gou Q; Zhang CZ; Sun ZH; Wu LG; Chen Y; Mo ZQ; Mai QC; He J; Zhou ZX; Shi F; Cui W; Zou W; Lv L; Zhuang WH; Xu RD; Li WK; Zhang J; Du HW; Xiang JX; Wang HZ; Hou T; Li ST; Li Y; Chen XM; Zhou ZJ
    ESMO Open; 2021 Dec; 6(6):100275. PubMed ID: 34653800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinoma.
    Yamamoto Y; Uemura M; Fujita M; Maejima K; Koh Y; Matsushita M; Nakano K; Hayashi Y; Wang C; Ishizuya Y; Kinouchi T; Hayashi T; Matsuzaki K; Jingushi K; Kato T; Kawashima A; Ujike T; Nagahara A; Fujita K; Imamura R; Nakagawa H; Nonomura N
    Cancer Sci; 2019 Feb; 110(2):617-628. PubMed ID: 30536551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bile-Based Cell-Free DNA Analysis Is a Reliable Diagnostic Tool in Pancreatobiliary Cancer.
    Driescher C; Fuchs K; Haeberle L; Goering W; Frohn L; Opitz FV; Haeussinger D; Knoefel WT; Keitel V; Esposito I
    Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33375555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotyping of circulating cell-free DNA enables noninvasive tumor detection in myxoid liposarcomas.
    Braig D; Becherer C; Bickert C; Braig M; Claus R; Eisenhardt AE; Heinz J; Scholber J; Herget GW; Bronsert P; Fricke A; Follo M; Stark GB; Bannasch H; Eisenhardt SU
    Int J Cancer; 2019 Aug; 145(4):1148-1161. PubMed ID: 30779112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal Copy-Number Alteration Analysis in Plasma Cell-Free DNA of Neuroendocrine Neoplasms is a Novel Specific Biomarker for Diagnosis, Prognosis, and Follow-up.
    Boons G; Vandamme T; Mariën L; Lybaert W; Roeyen G; Rondou T; Papadimitriou K; Janssens K; Op de Beeck B; Simoens M; Demey W; Dero I; Van Camp G; Peeters M; Op de Beeck K
    Clin Cancer Res; 2022 Jan; 28(2):338-349. PubMed ID: 34759042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genotyping of circulating tumor DNA in cholangiocarcinoma reveals diagnostic and prognostic information.
    Ettrich TJ; Schwerdel D; Dolnik A; Beuter F; Blätte TJ; Schmidt SA; Stanescu-Siegmund N; Steinacker J; Marienfeld R; Kleger A; Bullinger L; Seufferlein T; Berger AW
    Sci Rep; 2019 Sep; 9(1):13261. PubMed ID: 31519967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.
    Churi CR; Shroff R; Wang Y; Rashid A; Kang HC; Weatherly J; Zuo M; Zinner R; Hong D; Meric-Bernstam F; Janku F; Crane CH; Mishra L; Vauthey JN; Wolff RA; Mills G; Javle M
    PLoS One; 2014; 9(12):e115383. PubMed ID: 25536104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.